CLRB - Cellectar Biosciences Is An 'Attractive Acquisition Target' According To This Analyst - Here's Why | Benzinga
Monday, Cellectar Biosciences Inc (NASDAQ:CLRB) announced that iopofosine I 131 combined with external beam radiation therapy (EBRT) was safe and tolerated in a SPORE Grant-supported investigator-initiated Phase 1 trial.
The twelve patients treated for locoregionally recurrent head and neck squamous cell carcinoma previously received chemoradiation alone (42%), surgery (58%) or surgery combined with radiation or chemoradiation (92%).
Complete remission was achieved in 64% of patients, with an ORR of 73% (n=11).
Before treatment with iopofosine I 131, six patients had multiple recurrence, and one had metastatic disease.
Additionally, the study demonstrated the durability of tumor control with an overall survival of 67% and progression-free survival of 42% at 12 months.
Overall, eleven patients (92%) experienced a treatment-related adverse event.
The most common treatment-related adverse events of any ...